menu
    • menu
    [{"orgOrder":0,"company":"Chongqing Zhifei Biological Products","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Recombinant Human Papillomavirus Quadrivalent Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chongqing Zhifei Biological Products","amount2":14.800000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":14.800000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Chongqing Zhifei Biological Products \/ Merck & Co. Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Chongqing Zhifei Biological Products \/ Merck & Co. Inc."},{"orgOrder":0,"company":"Chongqing Zhifei Biological Products","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"Adjuvanted Recombinant Zoster Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chongqing Zhifei Biological Products","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chongqing Zhifei Biological Products \/ Chongqing Zhifei Biological Products","highestDevelopmentStatusID":"12","companyTruncated":"Chongqing Zhifei Biological Products \/ Chongqing Zhifei Biological Products"}]

    Find Clinical Drug Pipeline Developments & Deals by Chongqing Zhifei Biological Products

    Menu

    Chongqing Zhifei Biological Products

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Chongqing Zhifei Biological Products

                            China arrow
                            PackExpo
                            Not Confirmed

                            Chongqing Zhifei Biological Products

                            China arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adjuvanted Recombinant Zoster Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : GSK

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            GSK and Zhifei Announce Exclusive Strategic Vaccine Partnership in China

                            Details : Under the partnership, Zhifei will co-promote GSK’s shingles vaccine, Shingrix (recombinant zoster vaccine or RZV), a non-live, recombinant subunit vaccine in China for an initial three-year period.

                            Brand Name : Shingrix

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 09, 2023

                            Lead Product(s) : Adjuvanted Recombinant Zoster Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : GSK

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Chongqing Zhifei Biological Products

                            China arrow
                            PackExpo
                            Not Confirmed

                            Chongqing Zhifei Biological Products

                            China arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human Papillomavirus Quadrivalent Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Merck & Co

                            Deal Size : $14,800.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            MSD and Zhifei Renew Collaboration on Vaccines

                            Details : Under the collaboration, Zhifei will continue to purchase five vaccine products including, 4-valent and 9-valent HPV vaccine, Gardasil (recombinant human papillomavirus quadrivalent vaccine), pentavalent rotavirus vaccine and other agreed products from M...

                            Brand Name : Gardasil

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            January 21, 2023

                            Lead Product(s) : Recombinant Human Papillomavirus Quadrivalent Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Merck & Co

                            Deal Size : $14,800.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth